Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Cryoport, Inc. (NASDAQ:CYRX) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.29.

Several brokerages have issued reports on CYRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company. Finally, Roth Mkm dropped their target price on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, November 8th.

Cryoport Stock Performance

Shares of CYRX opened at $6.73 on Friday. Cryoport has a 12-month low of $5.32 and a 12-month high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The company has a market cap of $332.66 million, a PE ratio of -1.99 and a beta of 1.59. The stock has a 50-day moving average price of $7.79 and a 200-day moving average price of $7.82.

Insider Transactions at Cryoport

In other news, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares in the company, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $6.51, for a total transaction of $325,500.00. Following the sale, the chief executive officer now owns 731,897 shares of the company’s stock, valued at $4,764,649.47. This represents a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cryoport

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avanza Fonder AB bought a new stake in Cryoport during the 4th quarter valued at $64,000. Quarry LP bought a new stake in Cryoport during the 4th quarter valued at $69,000. Dynamic Technology Lab Private Ltd purchased a new position in Cryoport during the 3rd quarter valued at $82,000. Nebula Research & Development LLC increased its position in Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Cryoport by 135.5% during the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company’s stock valued at $100,000 after purchasing an additional 7,407 shares during the period. 92.90% of the stock is currently owned by institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.